Procter & Gamble Health Limited reported a profit after tax of ₹327 crore for the fiscal year ended March 31, 2026, marking a 30% increase compared to the comparable 12-month period last year. Sales for the period reached close to ₹1400 crore, reflecting a 16% growth driven by robust brand fundamentals, superior retail execution, and new user acquisition. The company delivered ₹35 crore in savings during the fiscal year through targeted productivity and savings programs, supporting margin expansion and value creation for stakeholders.

Financial Performance and Strategy

The company’s Integrated Growth Strategy, focusing on portfolio quality, superiority, productivity, and constructive disruption, underpinned the results. Over the past five years, absolute sales and profit have grown 1.4X and 1.8X respectively. Management highlighted that the improvement in gross margin for FY26 was primarily driven by a combination of productivity, favorable product mix, and pricing within National Pharmaceutical Pricing Authority (NPPA) regulations. The company recorded a balanced volume growth at mid-single digits in FY26.

Innovations and Portfolio Expansion

Management detailed three significant innovations launched during the year: Livogen Iron Gummies, Neurobion Nerve Pain Relief Cream, and Evion L5000 for Non-Alcoholic Fatty Liver Disease. These products collectively contributed early single-digit points of growth to the overall business. Livogen Iron Gummies achieved the highest category share on Amazon, ranking #1 on the platform in the Iron Gummies category. The company’s portfolio includes trusted brands such as Neurobion, Livogen, Evion, Seven Seas, Polybion, and Nasivion across categories including Vitamin B, Iron, Vitamin E, Omega-3, and Nasal Care.

Market Reach and Distribution

Procter & Gamble Health expanded its market penetration through changes in its Go-to-Market model over the last 2-3 years. The company added nearly 30,000 pharmacies and Healthcare Practitioners (HCPs) to its overall coverage as part of an initiative to expand into extra-urban white-space geographies. E-commerce remains a rapidly growing and material channel, with growth distributed across brands rather than being singularly focused.

Export Business and Outlook

The exports business witnessed encouraging growth in FY26, recording 3X growth in Nepal and high single-digit growth in Sri Lanka. This growth was bolstered by new product launches such as Neurobion Forte and Evion Forte. Management expressed confidence in continuing the growth momentum, citing increasing health consciousness, the expanding Vitamin, Mineral, and Supplements (VMS) market, and a shift towards preventive healthcare as key drivers.

Procter & Gamble Health Limited will host a virtual connect meeting with analysts and institutional investors on June 18, 2026, to engage with the investment community. The session is scheduled to begin at 2:30 p.m. IST and will be conducted via virtual mode. The company confirmed that no unpublished price sensitive information will be disclosed during this interaction.

Institutional investors and analysts interested in participating are required to complete their registration by June 8, 2026. The meeting link and specific access details will be shared separately only with those who have successfully registered. This procedural step ensures that only verified participants can join the discussion.

The meeting serves as a platform for the company to interact with stakeholders without sharing material non-public information. Participants can direct any queries regarding the registration process or the event to the designated company official via email.

Meeting Details

The registration deadline is strictly set for June 8, 2026. Procter & Gamble Health has emphasized that the session is purely for informational purposes and will not involve the disclosure of any unpublished price sensitive data.